Document Detail


Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance.
MedLine Citation:
PMID:  11481566     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Impaired myocardial flow reserve (MFR) in patients with familial hypercholesterolemia (FH) without evidence of ischemia has been reported. However, it has not been clarified whether diminished MFR in such male or female patients with FH can be reversed by simvastatin. METHODS AND RESULTS: Sixteen patients with FH and 16 age-matched control subjects were studied. All patients were proved to have no evidence of exercise stress-induced myocardial ischemia. Baseline myocardial blood flow (MBF) and MBF during dipyridamole administration (MBF [DP]) were measured with positron emission tomography and nitrogen 13 ammonia; MFR was then calculated before and 9 to 15 months after therapy with simvastatin (5-10 mg/day). Total cholesterol level was significantly higher in patients with FH (277 +/- 49.0) than in control subjects (190 +/- 14.9) but was normalized after lipid-lowering therapy (205 +/- 40.3). Baseline MBF was comparable among FH patients before (77.6 +/- 11.6 mL/min/100 g) and after therapy (74.5 +/- 9.62 mL/min/100 g) and control subjects (78.5 +/- 29.9 mL/min/100 g). However, MBF (DP) in FH patients before therapy (178 +/- 50.9 mL/min/100 g) was significantly lower than that in control subjects (282 +/- 148 mL/min/100 g) and was significantly improved after therapy (228 +/- 91.6 mL/min/100 g, P <.05). In fact, there was no statistically significant difference in the MBF (DP) value in FH patients after therapy compared with that in control subjects (P =.09). MFR significantly improved after therapy in patients with FH (3.33 +/- 1.19 vs 2.27 +/- 0.625, P <.01) and was then statistically comparable to that in control subjects (3.54 +/- 1.11). Improvement of MFR was observed whether MBF (DP) before therapy was greater than or less than 200 mL/min/100 g. MFR was improved in both male and female patients with FH. There was a significant relationship between percent change in plasma total cholesterol concentration and percent change in MFR before and after lipid-lowering therapy (r = -0.57, P <.05). CONCLUSIONS: Diminished MFR in patients with FH without evidence of ischemia can be reversed by moderate- to long-term simvastatin therapy without gender variance.
Authors:
I Yokoyama; K Yonekura; Y Inoue; K Ohtomo; R Nagai
Related Documents :
11271906 - Fatal lipid embolism following intraarterial angiography at an early stage of arteriosc...
11718676 - Serum lipid metabolism abnormalities and change in lipoprotein contents in patients wit...
22237746 - Acute kidney injury following acute liver failure: potential role of systemic cadmium m...
618626 - The rate of atherosclerosis change during treatment of hyperlipoproteinemia.
11817266 - Retrospective study of topiramate in a paediatric population with intractable epilepsy ...
8501496 - Prognostic role of serum beta 2-microglobulin in hodgkin's disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology     Volume:  8     ISSN:  1071-3581     ISO Abbreviation:  J Nucl Cardiol     Publication Date:    2001 Jul-Aug
Date Detail:
Created Date:  2001-08-01     Completed Date:  2001-09-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9423534     Medline TA:  J Nucl Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  445-51     Citation Subset:  IM    
Affiliation:
Department of Cardiovascular Medicine, University of Tokyo, Graduate School of Medicine, Tokyo, Japan. yokocham-tky@umin.u-tokyo.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticholesteremic Agents / therapeutic use*
Cholesterol / blood
Coronary Circulation / drug effects*
Dipyridamole / diagnostic use
Electrocardiography
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hyperlipoproteinemia Type II / blood,  drug therapy*,  physiopathology
Male
Middle Aged
Simvastatin / therapeutic use*
Tomography, Emission-Computed
Vasodilator Agents / diagnostic use
Chemical
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Vasodilator Agents; 57-88-5/Cholesterol; 58-32-2/Dipyridamole; 79902-63-9/Simvastatin
Comments/Corrections
Comment In:
J Nucl Cardiol. 2001 Jul-Aug;8(4):528-32   [PMID:  11481576 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prediction of severe coronary artery disease and long-term outcome in patients undergoing vasodilato...
Next Document:  Myocardial perfusion in patients with total occlusion of a single coronary artery with and without c...